📰 Early Access Program News
Page 36 - Early Access Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Early Access Program. Real-time updates on events, politics, business and more.
April 1, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
March 31, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
March 31, 2022
- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen in multiple high-value indications - Company
March 23, 2022
At GTC 2022 this week NVIDIA has announced the launch of its new Omniverse Cloud platform offering a suite of cloud services providing creators,
March 17, 2022
Data from 76 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013 will be presented. Oral presentation will highlight MaaT013's potential in improving survival outcome for
March 16, 2022
AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer GlobeNewswire March 16, 2022 Data seen to date indicates that Ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic...
March 16, 2022
Data seen to date indicates that Ampligen (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer In a single-center
March 8, 2022
Ampligen (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus
March 8, 2022
MAS Gold Corp (TSX-V:MAS, OTCQB:MSGCF) said it has completed drilling at the North Lake Deposit on its wholly-owned Preview North property in the La Ronge...
March 8, 2022
AIM ImmunoTech Inc (NYSE:AIM) has welcomed positive data from a study using Ampligen to treat advanced and metastatic pancreatic cancer patients, which...